Fifty years after thalidomide; What role for drug regulators?

British Journal of Clinical Pharmacology

Volumn 74, Issue 5, 2012, Pages 731-733

  Eichler, Hans Georg ^a   Abadie, Eric ^a,b   Baker, Mary ^a,c   Rasi, Guido ^a  

^a EUROPEAN MEDICINES AGENCY   (United Kingdom)

^b AFSSAPS   (France)

^c European Federation of Neurogical Associations (EFNA)   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

THALIDOMIDE;

DECISION MAKING; DRUG MANUFACTURE; GOVERNMENT; HUMAN; INFORMED CONSENT; LICENCE; MULTIPLE SCLEROSIS; NOTE; PATIENT CARE; PRIORITY JOURNAL; PUBLIC HEALTH; TERATOGENICITY; UNCERTAINTY;

DECISION MAKING; DRUG AND NARCOTIC CONTROL; DRUG APPROVAL; DRUG DESIGN; HUMANS; TERATOGENS; THALIDOMIDE;

EID: 84867365934     PISSN: 03065251     EISSN: 13652125     Source Type: Journal    
DOI: 10.1111/j.1365-2125.2012.04255.x     Document Type: Note

References (4)

1. ClinicalTrials.gov (website): About the ClinicalTrials.gov Results Database; http://www.clinicaltrials.gov/ct2/info/results (accessed 26 September 2012).
2. Beasley BN, Unger EF, Temple R. Anticoagulant options - Why the FDA approved a higher but not a lower dose of dabigatran. New Engl J Med 2011; 364: 1788-90.
3. Kramer J. Balancing the benefits and risks of inhaled long-acting beta-agonists - the influence of values. New Engl J Med. 2009: 360: 1592-5.
4. Benefit-risk methodology project; report form Work Package 3; EMA website: http://www.ema.europa.eu/docs/en_GB/document_library/Report/2011/09/WC500112088.pdf (accessed 26 September 2012).